# Regeneron Pharmaceuticals, Inc. (REGN) — Q4-2015 Earnings Results

**Report date:** 2016-02-09 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q4-2015

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Down 6.29%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.83 | N/A | +5.01% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the EPS results, indicating a commitment to pipeline development. However, they did not provide specific guidance for future performance.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> Our focus remains on advancing our pipeline.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron Pharmaceuticals reported better-than-expected earnings per share, but the stock fell by 6.29% following the announcement. Investors may have reacted negatively due to the lack of revenue details and guidance. The cautious tone from management suggests a focus on long-term growth rather than immediate financial targets.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q4-2015_